# Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

> **NCT00520013** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 60 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Papillary Serous Mullerian Tumor
- Clear Cell Mullerian Tumor

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** erlotinib
- **DRUG:** paclitaxel
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00520013
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-10
- **Final completion:** 2013-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520013, "Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00520013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*